Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
Journal of Biological Regulators and Homeostatic Agents · 2020-03 · 34 (2) · 1
DOI: 10.23812/conti-e ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Biological Regulators and Homeostatic Agents, 2020-03. Verfasst von P Conti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Medical School, University of Chieti, Chieti, Italy. Die Arbeit wurde bisher 213-mal zitiert (Crossref).
Abstract (Originalsprache)
COVID-19 (coronavirus disease-19) involves humans as well as animals and may cause serious damage to the respiratory tract including the lung. This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6. The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Ra receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2. The suppression of IL-1b by IL-37 in inflammatory state induced by COVID-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1b and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by COVID-19, providing a new relevant strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Postgraduate Medical School, University of Chieti, Chieti, Italy.
- Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.
- School of Pharmacy, University of Camerino, Camerino, Italy.
- Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.
- University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.
- Aristotelian University, Thessaloniki, Greece.
Zitieren
APA
Conti, P., Ronconi, G., Caraffa, A., Gallenga, C. E., Ross, R., Frydas, I., & Kritas, S. K. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents, 34(2), 1. https://doi.org/10.23812/conti-e
Vancouver
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies. Journal of Biological Regulators and Homeostatic Agents. 2020;34(2):1. doi:10.23812/conti-e
BibTeX
@article{Conti2020,
author = {Conti, P and Ronconi, G and Caraffa, A and Gallenga, C and Ross, R and Frydas, I and Kritas, S},
title = {Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies},
journal = {Journal of Biological Regulators and Homeostatic Agents},
year = {2020},
volume = {34},
number = {2},
pages = {1},
doi = {10.23812/conti-e}
}
EUVIMED